Literature DB >> 6848181

Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells.

B Singh, R S Gupta.   

Abstract

The mutagenic responses of 13 antineoplastic drugs, namely, chlorambucil, busulfan, lomustine, dacarbazine, Adriamycin, daunomycin, bleomycin, VM-26, VP16-213, ellipticine, actinomycin D, mitomycin C, and cis-diamminedichloroplatinum(II) have been determined in two different assay systems in Chinese hamster ovary cells which measure mutation induction at multiple genetic loci and the frequencies of sister chromatid exchanges. The five genetic loci whose responses have been measured include those conferring resistance to 6-thioguanine (Thgr or TGr), ouabain, emetine, methylglyoxal bis(guanylhydrazone), and 5,6-dichlororibofuranosylbenzimidazole; of these, only the Thgr marker affects a function (hypoxanthine-guanine phosphoribosyltransferase, hgprt locus) which is not essential for cellular growth. All of these drugs showed a dose-dependent increase in mutation frequency at the hgprt locus, but their responses at other genetic loci differed greatly and showed marked specificity for different chemical classes of the drugs. The observed locus-specific differences in response to these drugs suggest that they may differ in terms of their accessibility or affinity to different chromosomal regions. All of these drugs also led to a significant increase in the frequency of sister chromatid exchanges, and a very good correlation was observed between the activity of these drugs in the sister chromatid exchange assay and the mutagenic response of the hgprt locus. Of the drugs which were examined, VM-26, VP16-213, chlorambucil, mitomycin C, and cis-diamminedichloroplatinum(II) showed a particularly strong response in both of these assay systems. In terms of the minimum concentration which gave a mutagenic response, the drugs differed from each other by a factor of about 100,000, with actinomycin D, VM-26, and daunomycin being mutagenic in the range of 3 x 10(-8) to 1 x 10(-7) M, whereas dacarbazine produced a weak mutagenic response only at about 2 x 10(-3) M.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848181

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  A revisit of the mode of interaction of small transcription inhibitors with genomic DNA.

Authors:  Dipak Dasgupta; Parijat Majumder; Amrita Banerjee
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

2.  Relationship between spermatogonial stem cell survival and testis function after cytotoxic therapy.

Authors:  M L Meistrich
Journal:  Br J Cancer Suppl       Date:  1986

3.  Induction of sister chromatid exchanges by inhibitors of topoisomerases.

Authors:  M Lim; L F Liu; D Jacobson-Kram; J R Williams
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

4.  Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death.

Authors:  N A Berger; S Chatterjee; J A Schmotzer; S R Helms
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 5.  Drug resistance and DNA repair.

Authors:  M Fox; J J Roberts
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 6.  Can cancer chemotherapy enhance the malignant behaviour of tumours?

Authors:  T J McMillan; I R Hart
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Intracellular forms of Drosophila topoisomerase II detected with monoclonal antibodies.

Authors:  G Hadlaczky; T Praznovszky; J Sófi; A Udvardy
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

8.  Protein binding, sister chromatid exchange and expression of oncogene proteins in patients treated with cisplatinum (cisDDP)-based chemotherapy.

Authors:  F Perera; H K Fischman; K Hemminki; P Brandt-Rauf; H L Niman; S Smith; E Toporoff; K O'Dowd; M X Tang; W Y Tsai
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

Review 9.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

10.  Enhanced experimental metastatic capacity of a murine melanoma following pre-treatment with anticancer drugs.

Authors:  T J McMillan; I R Hart
Journal:  Clin Exp Metastasis       Date:  1986 Oct-Dec       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.